WebSparingVision is a biotechnology company focused on the discovery and development of a therapeutic approach for the treatment of blinding inherited retinal diseases such as retinitis pigmentosa. It serves clients in the healthcare sector. It was founded in 2016 and is based in Paris, France. Headquarters Location 5/7 avenue Percier CS40230 WebCAMBRIDGE, Mass., May 18, 2024 – Vedere Bio II, Inc., a company developing next generation ocular gene therapies designed for vision restoration and preservation for …
SparingVision (@SparingVision) / Twitter
Web3. feb 2024 · SparingVision, founded in 2016, has 25 employees overall and opened its Philadelphia office this week with two people. ... SparingVision raised $71 million in its Series A financing that was ... Web22. okt 2024 · SparingVision is a biotechnology company specialized in the research and development of an innovative therapeutic approach for the treatment of inherited retinal degenerative diseases such as retinitis pigmentosa. … gwyn lord of cinder roblox piano
EG 427 announces €12 million Series A financing to advance
Web14. sep 2024 · Paris, September 14, 2024 – SparingVision (“the Company”), a genomic medicine company developing vision-saving treatments for ocular diseases, today announces that it has raised €75 million in a... Web20. apr 2024 · SparingVision’s SPVN06 already addresses mid-stages of rod-cone dystrophies, while GAMUT’s SPVN20 addresses late stages: giving SparingVision the opportunity to address different stages and potentially combine both products. ... either alone or together in a series of treatments - to address a broader population of RP … WebStéphane was appointed Chief Executive Officer of SparingVision concurrently to the first closing of the series A financing in August 2024. He is also Chairman of the Board of the … gwyn morgan classics